Welcome to our dedicated page for Ekso Bionics Holdings news (Ticker: EKSO), a resource for investors and traders seeking the latest updates and insights on Ekso Bionics Holdings stock.
Ekso Bionics Holdings, Inc. (Symbol: EKSO) is a pioneering company in the field of robotic exoskeletons, or wearable robots, aimed at augmenting human strength, endurance, and mobility. Since its founding in 2005, Ekso Bionics has developed cutting-edge technology that has enabled thousands of people with paralysis to take millions of steps that would otherwise be impossible. Headquartered in Richmond, California, with international offices in London, the company has been a leader in both the healthcare and industrial markets.
Ekso Bionics operates through two main segments: EksoHealth and EksoWorks. The EksoHealth segment, which generates the majority of the company's revenue, focuses on designing, engineering, manufacturing, and selling exoskeletons for medical applications. These devices are worn over clothing and controlled by trained operators to assist individuals with mobility challenges. The EksoWorks segment, on the other hand, targets able-bodied users by creating exoskeleton devices that help them perform strenuous, repetitive tasks for extended periods.
Over the years, Ekso Bionics has been at the forefront of innovation, continuously pushing the boundaries of what robotic exoskeletons can achieve. Their products have not only redefined the scope of physical rehabilitation but have also found significant applications in various industrial settings, allowing workers to carry out challenging tasks more efficiently. Ekso Bionics is committed to breaking physical limitations and helping users reach new heights of capability.
For the latest updates, partnerships, and developments related to Ekso Bionics and their stock performance, visit StockTitan regularly.
Ekso Bionics Holdings (Nasdaq: EKSO) announced the appointment of Jerome Wong as Interim Chief Financial Officer following Jack Glenn's resignation effective June 17, 2022. Wong, previously the Controller for five years, brings over 20 years of finance experience. His appointment is expected to provide a seamless transition as the company explores growth opportunities. Glenn's departure is amicable and unrelated to any company disputes. The company continues to innovate in exoskeleton technology, enhancing human capabilities in medical and industrial applications.
Ekso Bionics Holdings, listed under the symbol EKSO, will present at the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The pre-recorded presentation will be available on-demand starting at 4:00 AM PT / 7:00 AM ET on May 24, 2022, and can be accessed on the investor section of the company's website.
As a leader in exoskeleton technology, Ekso Bionics focuses on enhancing human strength and mobility for both medical and industrial applications. Established in 2005, the company is headquartered in the San Francisco Bay Area.
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) reported financial results for Q1 2022, achieving $2.6 million in revenue, up from $1.9 million in Q1 2021. The company booked 23 EksoNR units and secured its largest multi-unit order. Gross profit dropped by 2% to $1.2 million, decreasing gross margin to 47% due to increased service costs. Net loss grew to $4.6 million, or $0.36 per share, compared to a loss of $3.7 million in Q1 2021. Cash reserves were $36.2 million as of March 31, 2022, down from $40.4 million at year-end 2021.
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) announced it will release its first quarter 2022 financial results on April 28, 2022, after trading hours. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET, where management will discuss financial outcomes and business developments. Investors can access the live webcast through the company's website, with a replay available for one month post-event. Ekso Bionics specializes in exoskeleton technology, enhancing human strength and mobility in various applications.
Ekso Bionics Holdings reported a record revenue of $4.1 million for Q4 2021, up from $2.3 million in Q4 2020. The company achieved a gross margin of approximately 59%. They booked 30 EksoNR units and posted a reduced net loss of $2.9 million, down from $4.0 million YoY. For the full year, revenue was $11.2 million, marking a 27% increase from 2020. Cash on hand rose to $40.4 million. Management appointed Steven Sherman as CEO and Scott Davis as President/COO, emphasizing their focus on innovation in neurorehabilitation.
Ekso Bionics Holdings (Nasdaq: EKSO) will release its financial results for Q4 and full year 2021 on February 24, 2022, after market close. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results and recent business developments. The live webcast will be accessible on the company's website. Founded in 2005, Ekso Bionics specializes in exoskeleton technology aimed at enhancing mobility and strength in medical and industrial sectors.
Ekso Bionics Holdings announced the departure of CEO Jack Peurach effective January 21, 2022, to pursue other endeavors. Steven Sherman, the current Chairman, will step in as CEO starting January 22, 2022, while Scott Davis is promoted to President and COO. The board expressed confidence in future growth after reporting record revenue for Q4, driven by momentum in rehabilitation and industrial segments. Sherman aims to expand the product portfolio and align his compensation with shareholder interests by opting for equity over cash salary.
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) reported record preliminary revenue for Q4 2021 between $3.9 million and $4.1 million, showing a 77% increase from Q4 2020's $2.3 million. Total revenue for fiscal 2021 reached an estimated $11.1 million to $11.3 million, up 26% from $8.9 million in 2020. Cash on hand surged to $40.4 million from $12.9 million a year earlier. CEO Jack Peurach indicated strong growth in both rehabilitation and industrial sectors, enhancing their market presence.
Ekso Bionics, a leader in exoskeleton technology, announced participation in the H.C. Wainwright BioConnect Virtual Conference from January 10-13, 2022. The management will engage in a fireside chat available on-demand starting January 10 at 4:00 AM PT. This chat will be accessible throughout the conference on the company's investor website. Founded in 2005, Ekso Bionics aims to enhance strength and mobility through innovative wearable robots. The company is publicly traded on Nasdaq under the symbol EKSO.
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) has appointed Corinna E. Lathan, Ph.D., to its Board of Directors. Dr. Lathan brings over 20 years of experience in robotics and biomedical engineering, having co-founded AnthroTronix. She currently serves on the board of PTC, Inc. and has held academic positions at prominent universities. CEO Jack Peurach expressed confidence in Dr. Lathan's ability to provide unique insights as the company aims to advance its innovative exoskeleton technologies for medical and industrial applications.
FAQ
What is the current stock price of Ekso Bionics Holdings (EKSO)?
What is the market cap of Ekso Bionics Holdings (EKSO)?
What does Ekso Bionics Holdings, Inc. do?
Where is Ekso Bionics headquartered?
What are the main segments of Ekso Bionics?
What does the EksoHealth segment specialize in?
What does the EksoWorks segment focus on?
How has Ekso Bionics impacted people with paralysis?
In which regions does Ekso Bionics operate?
How can I get in touch with Ekso Bionics for investor relations?
What innovations has Ekso Bionics brought to the industrial market?
How does Ekso Bionics contribute to physical rehabilitation?
